Author:
Gaze Mark N.,Gains Jennifer E.,Bomanji Jamshed B.
Publisher
Springer International Publishing
Reference41 articles.
1. Bodei L, Mueller-Brand J, Baum RP, Pavel ME, Hörsch D, O’Dorisio TM, O’Dorisio TM, Howe JR, Cremonesi M, Kwekkeboom DJ, Zaknun JJ (2013) The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 40:800–816
2. Bodey RK, Flux GD, Evans PM (2003) Combining dosimetry for targeted radionuclide and external beam therapies using the biologically effective dose. Cancer Biother Radiopharm 18:89–97
3. British Institute of Radiology Molecular Radiotherapy Working Party (2011) BIR Report 23: molecular radiotherapy in the UK: current status and recommendations for further investigation. British Institute of Radiology, London. ISBN13: 978-0-905749-70-9
4. Darrouzet E, Lindenthal S, Marcellin D, Pellequer JL, Pourcher T (1838) The sodium/iodide symporter: state of the art of its molecular characterization. Biochim Biophys Acta 2014:244–253, Epub 2013 Aug 27
5. Delpassand ES, Samarghandi A, Zamanian S, Wolin EM, Hamiditabar M, Espenan GD, Erion JL, O’Dorisio TM, Kvols LK, Simon J, Wolfangel R, Camp A, Krenning EP, Mojtahedi A (2014) Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience. Pancreas 43:518–525
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献